Sign Up
SB 77 Kentucky Senate · 2026 Regular Session

AN ACT relating to ibogaine research in the Commonwealth.

Summary
Create new sections of KRS Chapter 218A to define terms; establish the ibogaine research and intellectual property fund to be administered by the Department of Agriculture for the purpose of allowing the department to enter a public-private partnership with a drug developer to conduct a clinical drug development trial or trials related to the use of ibogaine for the treatment of opioid use disorder, co-occurring substance use disorder, or any other neurological or mental health condition for which ibogaine demonstrates efficacy; establish requirements for the department related to how it contracts with a drug developer related to ibogaine research and intellectual property; appropriate $21 million from the opioid abatement trust fund to the ibogaine research and intellectual property development fund in fiscal year 2026-2027 and in fiscal year 2027-2028; APPROPRIATION; EMERGENCY.
Issues: ✓ Budget & TaxesSupports Budget & TaxesBill creates new appropriation fund (KRS Chapter 218A) for ibogaine research, directly allocating state funds to support public health initiative under Budget & Financial Administration.95% confidence ✓ HealthcareSupports HealthcareFunds clinical trials for opioid use disorder and mental health treatment via new appropriation under public health initiatives.95% confidence
Bill status signed all 5 stages cleared
Introduction
Jan 2026
Committee Review
Apr 2026
Senate Passage
Apr 2026
House Passage
Apr 2026
Signed into Law
Apr 2026
Introduced Jan 13, 2026 Signed Apr 14, 2026
Maddy AI version diff · 1 comparison

What changed between versions

Introduced → Current/Final · 5 edits
MODERATE
The bill was amended to remove a declaration of emergency and update the header to reflect its vetoed and overridden status. Substantively, the funding section was expanded to explicitly include private funds alongside public ones, and the contract requirements were strengthened to mandate that drug developers match state investments dollar-for-dollar while conducting trials exclusively within Kentucky using in-state staff and participants.
Scope change
The bill's scope regarding funding sources was broadened to include private contributions, and the geographic scope of clinical trials was strictly limited to within the Commonwealth of Kentucky.
TECHNICAL

Removed the declaration of an emergency, which is no longer necessary for the bill's provisions.

Updated the document header to indicate the bill was vetoed by the Governor and subsequently overridden by the legislature.

FISCAL

Expanded the types of funds the research trust can accept to explicitly include private donations, grants, and gifts, not just state and federal money.

REQUIREMENT

Added a strict requirement that any drug developer receiving state funds must match that investment dollar-for-dollar with their own funding.

Mandated that all clinical trials funded by the state must be conducted exclusively within Kentucky, using only in-state clinicians, facilities, and study participants.

Floor votes · Senate Mar 13, 2026

How they voted

41–2
Passed · 1 other
Total votes 44
Mar 13, 2026
D Democratic6
5 Yea 1
83% Yea
R Republican38
36 Yea 2 Nay
94% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
33
Key actions
11
Committee
8
Apr 14, 2026
Lower · Passed
enrolled, signed by Speaker of the House
lower
Apr 14, 2026
Upper · Passed
enrolled, signed by President of the Senate
upper
Apr 14, 2026
Upper · Passed
passed 77-18
upper
Apr 14, 2026
Vetoed
posted for consideration of Governor's veto
upper
Apr 14, 2026
Committee
to Rules (H)
lower
Apr 14, 2026
Upper · Passed
passed 31-6
upper
Apr 14, 2026
Vetoed
veto overridden
upper
Apr 14, 2026
Vetoed
posted for passage for consideration of Governor's veto
upper
Apr 14, 2026
Committee
to Rules (S)
upper
Apr 13, 2026
Vetoed
Vetoed
upper
Apr 1, 2026
Lower · Passed
enrolled, signed by Speaker of the House
lower
Apr 1, 2026
Upper · Passed
enrolled, signed by President of the Senate
upper
Apr 1, 2026
Upper · Passed
3rd reading, passed 82-8
upper
Mar 24, 2026
Upper · Passed
reported favorably, 1st reading, to Calendar
upper
Mar 20, 2026
Committee
to Veterans, Military Affairs, & Public Protection (H)
lower
Mar 17, 2026
Committee
to Committee on Committees (H)
lower
Mar 13, 2026
Upper · Passed
3rd reading, passed 35-2 with Committee Substitute (1) and Committee Amendment (1-title)
upper
Mar 11, 2026
Upper · Passed
reported favorably, 1st reading, to Calendar with Committee Substitute (1) and Committee Amendment (1-title)
upper
Mar 9, 2026
Committee
to Health Services (S)
upper
Jan 13, 2026
Committee
to Committee on Committees (S)
upper
Jan 13, 2026
Introduced
introduced in Senate
upper
0 primary · 0 co-sponsors

Sponsors

No sponsor information available.